Skip to content
OpenCapital
Get started

Repligen RGEN Cash & Equivalents

Cash & Equivalents at other companies

TEC
Bio-TechneTECH
$209.82M+49.2%
Revvity logo
RevvityRVTY
$861.47M-24.3%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$3.28B-21.4%
Danaher logo
DanaherDHR
$5.7B+186%
Agilent Technologies logo
Agilent TechnologiesA
$1.81B+21.5%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$509M-2.7%

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×—
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's cash & equivalents?
Repligen (RGEN) reported cash & equivalents of $582.65M in Q1 2026.
How has Repligen's cash & equivalents changed year-over-year?
Repligen's cash & equivalents decreased by 16.4% year-over-year, from $697.23M to $582.65M.
What is the long-term trend for Repligen's cash & equivalents?
Over 5 years (2020 to 2025), Repligen's cash & equivalents has grown at a -4.6% compound annual growth rate (CAGR), from $717.29M to $566.02M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.